The essence of our clinical findings is consistent with an earlier randomized, placebo-controlled trial of GDNF in Parkinson’s disease (Lang et al., 2006), although the latter used continuous diffusion-dependent intraputamenal delivery resulting in spatially limited putamen delivery (Salvatore et al., 2006). This evidence concerns the gene GDNF and Parkinson disease.